the aid library

Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS)

Communicable Disease Control Branch - Manitoba Health (2010) C2

Communicable Disease Control Branch Communicable Disease Management Protocol – Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), February 2010

WHO Prequalification of Diagnostics Programme - Public Report (Product: Rapid Test for Antibody to Human Immunodeficiency Virus (HIV) (Colloidal Gold Device), Number: PQDx 0005-005-00)

World Health Organization (2016) C_WHO

PQDx 0005-005-00 WHO PQDx PR May/2016, version 3.0

Pathophysiology of the human immunodeficiency virus

N. R. Calles; D. Evans; D.L. Terlonge Baylor International Pediatric AIDS Initiative (BIPAI) (2019) C2

Accessed: 03.09.2019

WHO Prequalification of Diagnostics Programme - Public Report (Product: ABONtm HIV 1/2/O Tri-Line Human Immunodeficiency Virus Rapid Test Device, Number: PQDx 0141-051-00)

World Health Organization (2017) C_WHO

PQDx 0141-051-00 WHO PQDx Public Report April/2017, version 5.0

Guidelines for the Management of Tuberculosis, Human Immunodeficiency Virus and Sexually-Transmitted Infections in Correctional facilities 2013

Department of Health, Republic of South Africa (2013) C1

The guidelines acknowledge that overcrowding, unhygienic conditions and high inmate turn over contribute to the spread of infectious diseases within correctional facilities. The document states that voluntary HIV counselling and testing must be offered to all inmates when they enter facilities, duri ... more

TB Elimination Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics

Centers for Disease Control and Prevention; National Center for HIVAIDS; TB Prevention; et al. (2012) C_CDC

August 2012

Philippines: Guidelines on Antiretroviral Therapy (ARV) among adults and adolescents with Human Immunodeficiency Virus (HIV) Infection

Republic of the Philippines, Dept. of Health (2009) C1

Uptake of HIV testing in Burkina Faso: an assessment of individual and community level determinants

Kirakoya-Samadoulougou F., K. Jean, M. Maheu-Giroux BMC Public Health (2017) C2

Previous studies have highlighted a range of individual determinants associated with HIV testing but few have assessed the role of contextual factors. The objective of this paper is to examine the influence of both individual and community-level determinants of HIV testing uptake in Burkina Faso.

Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях высокой распространенности ВИЧ-инфекции и ограниченных ресурсов

Delphine Sculier, Haileyesus Getahun, Reuben Granich World Health Organization, TB HIV working group, Stop TB Partnership (2011) C_WHO

Цель этого документа – повысить уровень осознания актуальности приоритетных направлений научных исследований по проблеме ТБ/ВИЧ (то есть по тем направлениям, кот ... more

Clinical Course and Outcome of Human Monkeypox in Nigeria

Ogoina, D.; Iroezindu, M.; Izibewule, J.H. et al. (2020) CC

In a retrospective review of hospital records of 40 human monkeypox cases from Nigeria, the majority developed fever and self-limiting vesiculopustular skin eruptions. Five deaths were reported. Compared to human immunodeficiency virus (HIV)–nega ... more

West & Central Africa HIV catch-up - WHO in an era of transformation

World Health Organisation (WHO) (2023) C_WHO

The Transformation Agenda (TA) ushered in an ambitious reform process intended to transform the World Health Organization (WHO) into an organization that is proactive, results-driven, accountable and which meets stakeholder expectations, towards transforming and improving public health services in t ... he African Region. It aimed to achieve a WHO that is pro-results, which optimally and creatively targets technical work as well as make operations more responsive, with greater effectiveness in both communications and partnerships. The Africa Region has been the epicentre of the human immunodeficiency virus (HIV) epidemic and it’s one of the leading causes of disease and death on the continent. The WHO, with partners, has worked tirelessly for many years to control the threat and reduce the negative impact of the disease. Since the early 2000s, significant progress has been made in the global fight against the scourge of HIV. However, the WCA subregion was falling concerningly behind ESA on several key indicators of progress. In 2016, the WHO joined UNAIDS, UNICEF and other partners in a call for a strong and urgent response to support WCA countries to develop catch-up plans to triple and fast-track ART coverage, to enable the region to catch up with ESA by the end of 2020. Implementation of a widespread test-and-treat strategy, coupled with the scale-up of differentiated service delivery (DSD) and mobilization of requisite funding, accelerated WCA’s progress towards this goal. The HIV treatment catch-up and fast-track plan has achieved its target of seeing the West and Central African region (WCA) catch up with the Eastern and Southern African region’s (ESA) antiretroviral coverage rate of 78% in 2021, albeit later than the 2020 target time frame. A 33% improvement was achieved in WCA, against 21% in ESA, between 2015–2020. WCA achieved a significant 42% increase, compared to ESA’s 23%, between 2015 and 2021, to see WCA draw level with ESA at 78%. In the Democratic Republic of the Congo (DRC) alone, progress of up to 47% was observed between 2015 and 2020, for example. In addition, 1.6 million more People Living with HIV (PLHIV) were enrolled on antiretroviral treatment (ART) between 2015 and 2020. more

Guía de Práctica Clínica - Problema de Salud AUGE N°18 Síndrome de la Inmunodeficiencia Adquirida VIH/SIDA

Ministerio de Salud, Gobierno de Chile (2022) C1

Pediátrico Recomendaciones GRADE accessed August 2022

Global AIDS Response Progress Report Myanmar

The Republic of the Union of Myanmar, Ministry of Health (2015) C1

Reporting period: January 2014 – December 2014
The human immunodeficiency virus (HIV) epidemic in Myanmar is concentrated among men who have sex with men (MSM), people who inject drugs (PWID) and female sex workers (FSW). HIV prevalence in th ... more

Consolidated guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection
recommended

World Health Organization WHO (2016) C_WHO

2nd edition. These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structu ... more

Management of Buruli ulcer–HIV coinfection

World Health Organization WHO (2020) C_WHO

Technical Update Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited inf ... more

African Union Framework for Antimicrobial Resistance Control 2020–2025
recommended

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2021) CC

Reports of antimicrobial-resistant (AMR) microorganisms are increasing globally, threatening to render existing treatments ineffective against many infectious diseases. In Africa, AMR has already been documented to be a problem for human immunodeficiency ... more

Overview of Tuberculosis Coinfection with HIV in Ecuador 2010-2015

Torres, A.; M. Cedeño, R. Pinargote, M. Fors revistabionatura (2020) CC

Volumen 5 / Número 1 , 1025-1028 • http://www.revistabionatura.com To describe the behavior of Tuberculosis/Human Immunodeficiency Virus co-infection in a cohort of people affected by sensitive Tuberculosis in Ecuador from 01 January 2010 ... more

Knowledge, attitude and practices towards visceral leishmaniasis among HIV patients: A cross-sectional study from Bihar, India

Devipriya, J.; Gupta, A.; Veeri, B. et al. PLOS One (2021) CC

In the Indian state of Bihar, visceral leishmaniasis (VL) is a major public health issue that has been aggravated by the rising incidence of new Human immunodeficiency virus (HIV) infections. In endemic areas, the risk of VL infections in patients l ... more

WHO consolidated guidelines on drug-resistant tuberculosis treatment
recommended

World Health Organization WHO; Stop TB (2019) C_WHO

The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ... more